You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Roche, Shionogi, Janssen Pharmaceuticals, and Eisai will provide the charity with specimens from Alzheimer's disease patients who participated in clinical studies.
About $1.3 billion of revenues, or 19 percent, were related to COVID-19 products and services, and life sciences solutions revenues jumped 52 percent.
The targeted sequencing assay analyzes 12 genes and can be paired with the firm's BRCA gene testing kit.
The forum will gather information on issues surrounding SARS-CoV-2 testing and diagnostics from federal officials and the private sector.
The French diagnostics firm said the revenue decline was driven by a 17 percent drop in revenues from its in vitro diagnostics operations.
The company plans to use the proceeds of the round to fund ongoing development and commercialization of its point-of-care diagnostic platform.
The program is intended to help make testing for the virus more accessible to New Yorkers, the partners said.
Access Genetics' RT-PCR-based test is designed to detect viral RNA, while Megna Health's test is designed to detect antibodies against the SARS-CoV-2.
The RT-PCR-based test may only be performed by Framingham, Massachusetts-based BHD, which is a subsidiary of Eurofins Scientific.
The announcement follows a similar one from Becton Dickinson saying that HHS would buy its tests and platforms for coronavirus testing.
The assays are performed on nasal swab specimens self-collected by patients under the observation of a healthcare provider via telemedicine.
The firm intends to use about $25 million to $30 million of the net proceeds for the continued development and planned commercialization of its KidneyIntelX platform.
Significant revenue from molecular and rapid diagnostic testing for SARS-CoV-2 offset declines in core lab volumes.
The agreement is Oncocyte's second distribution deal this year following an agreement with Core Diagnostics to sell the test in Africa and the Middle East.
Under the original March agreement, Thermo Fisher was going to pay €39 per Qiagen share, a 23 percent premium that the amendment now raises to 35 percent.
The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder.
The firm's various COVID-19 molecular test offerings offset declines in core laboratory and point-of-care segments.
The Australian molecular diagnostics firm said it has signed agreements sell 1,025,000 of its American Depository Shares to several institutional investors.
The collaborators aim to develop lung cancer molecular diagnostic tests using molecular, clinical, and imaging-based artificial intelligence technologies.
Synlab will make a gastrointestinal testing service that is based on Microba's gut microbiome test available to its network of doctors and clinics.